Yueh-Han Hsu1, Chih-Hsin Muo2, Chun-Yi Liu3, Wen-Chen Tsai3, Chih-Cheng Hsu4, Fung-Chang Sung5, Chia-Hung Kao6. 1. Department of Public Health, China Medical University, Taichung City 404, Taiwan; Department of Health Services Administration, China Medical University, Taichung City 404, Taiwan; Department of Internal Medicine, Division of Nephrology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi City 600, Taiwan; Department of Nursing, Min-Hwei Junior College of Health Care Management, Tainan City 736, Taiwan. 2. Management Office for Health Data, China Medical University Hospital, Taichung City 404, Taiwan; School of Medicine, China Medical University, Taichung City 404, Taiwan. 3. Department of Public Health, China Medical University, Taichung City 404, Taiwan; Department of Health Services Administration, China Medical University, Taichung City 404, Taiwan. 4. Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Miaoli County 35053, Taiwan; Department of Health Services Administration, China Medical University and Hospital, Taichung City 404, Taiwan. 5. Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, Taichung City 404, Taiwan. 6. Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, Taichung City 404, Taiwan; Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung City 404, Taiwan. Electronic address: d10040@mail.cmuh.org.tw.
Abstract
BACKGROUND & AIMS: The relationship between hepatitis C virus (HCV) infection and peripheral arterial disease (PAD) development remains unclear. METHODS: Health insurance claims data were used to construct a cohort of HCV-infected patients diagnosed during the period 1998-2011. Patients younger than 20 years and those with history of hepatitis B or PAD were excluded. We selected 7641 HCV-infected patients and 30564 matched controls. The adjusted risk of developing PAD was analyzed using a multivariate Cox hazard model. RESULTS: The results show that the excess risk of PAD development in HCV-infected patients is 1.43-fold higher (95% CI=1.23-1.67) compared with non-HCV patients. The adjusted risk of PAD development increases with age; compared with the 20-34 year-old patients, the risk is 3.96-fold higher in HCV-infected patients aged 35-49 years, and 11.7-fold higher in those aged 65 years and above. CKD/ESRD has the highest risk for PAD (HR=1.80, 95% CI=1.29-2.53). HCV-infected patients with four comorbidities exhibit a substantially higher risk of developing PAD (HR=9.25, 95% CI=6.35-13.5). Excess risk of developing PAD is observed from the first year of follow-up till the third year. CONCLUSION: HCV-infected patients have an independently higher risk of developing PAD. HCV-infected patients with comorbidity have increased risk of developing PAD.
BACKGROUND & AIMS: The relationship between hepatitis C virus (HCV) infection and peripheral arterial disease (PAD) development remains unclear. METHODS: Health insurance claims data were used to construct a cohort of HCV-infectedpatients diagnosed during the period 1998-2011. Patients younger than 20 years and those with history of hepatitis B or PAD were excluded. We selected 7641 HCV-infectedpatients and 30564 matched controls. The adjusted risk of developing PAD was analyzed using a multivariate Cox hazard model. RESULTS: The results show that the excess risk of PAD development in HCV-infectedpatients is 1.43-fold higher (95% CI=1.23-1.67) compared with non-HCVpatients. The adjusted risk of PAD development increases with age; compared with the 20-34 year-old patients, the risk is 3.96-fold higher in HCV-infectedpatients aged 35-49 years, and 11.7-fold higher in those aged 65 years and above. CKD/ESRD has the highest risk for PAD (HR=1.80, 95% CI=1.29-2.53). HCV-infectedpatients with four comorbidities exhibit a substantially higher risk of developing PAD (HR=9.25, 95% CI=6.35-13.5). Excess risk of developing PAD is observed from the first year of follow-up till the third year. CONCLUSION:HCV-infectedpatients have an independently higher risk of developing PAD. HCV-infectedpatients with comorbidity have increased risk of developing PAD.
Authors: Parag Mahale; Eric A Engels; Ruosha Li; Harrys A Torres; Lu-Yu Hwang; Eric L Brown; Jennifer R Kramer Journal: Gut Date: 2017-06-20 Impact factor: 23.059
Authors: K W Chew; D Bhattacharya; T B Horwich; P Yan; K A McGinnis; C Tseng; M S Freiberg; J S Currier; A A Butt Journal: J Viral Hepat Date: 2017-04-10 Impact factor: 3.728
Authors: Luis M Beltrán; Alfonso Rubio-Navarro; Juan Manuel Amaro-Villalobos; Jesús Egido; Juan García-Puig; Juan Antonio Moreno Journal: Vasc Health Risk Manag Date: 2015-01-06